Peer-reviewed article
Pharmacological Treatment Strategies for Postpartum Depression
Vasiliu O ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a literature review of pharmacological treatments for postpartum depression in adults. It examines evidence for various antidepressant medications including SSRIs, other antidepressants, and newer agents like brexanolone. The review does not evaluate child well-being outcomes or impacts on children.
Key points
Limitations
This document focuses on maternal mental health treatment rather than child well-being. It does not evaluate how postpartum depression treatment affects children's development, health, or outcomes.
Abstract
Introduction Postpartum depression (PPD) is an important cause of discomfort and dysfunction that impair the quality of life and the daily functionality not only of the patient but also of her child and her family, in its entirety. New treatment options have been made available for this pathology, but their use is restricted by methodological aspects, like the difficulty of administration, lack of enough data regarding their long-term efficacy, and costs. Objectives To conduct a literature review in order to find the most evidence-based pharmacological interventions for PPD. Methods A literature review was performed through the main electronic databases (PubMed, CINAHL, SCOPUS, EMBASE) using the search paradigm “postpartum depression” AND “treatment” OR “pharmacological agents”. All papers published between January 2000 and August 2021 were included. Results Among the most evidence-based agents for PPD treatment are serotonin selective reuptake inhibitors (SSRIs). As individual agents, sertraline seems to be the most supported antidepressant by evidence from clinical trials, followed by escitalopram/citalopram, and fluoxetine. Other antidepressants supported by clinical data were venlafaxine, desvenlafaxine, nortriptyline, and bupropion. A 6-12 months maintenance treatment is considered optimal after remission, in women with a low risk of recurrence. Brexanolone, zuranolone, and ganaxolone are members of a new class of drugs studied for postpartum depression, but currently, only the first agent is FDA-approved for this indication. Conclusions SSRIs are the most supported by evidence treatments for PPD, and brexanolone is a drug with a new mechanism, dedicated to this pathology that provides new hope for recovery. Disclosure No significant relationships.